AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ONC · NASDAQ · Biotechnology

BeOne Medicines (ADR) (ONC)

Develops and commercializes oncology medicines through an in-house global model.

$368.08

After hours+0.13 (+0.04%)

At close$367.95(+0.62%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	781	634	752	929	1,002	1,128	1,117	1,315	1,412	1,498	1,513	1,705
Cost of revenue	96	106	125	138	170	161	165	165	197	142	167	175
Gross profit	685	529	627	791	831	967	952	1,151	1,216	1,356	1,346	1,531
	819	912	888	898	951	1,047	941	1,063	1,053	1,171	1,096	1,205
Research & development	453	494	461	454	496	542	482	525	524	615	541	612
Selling, general & administrative	366	417	427	444	455	505	459	538	529	555	555	593
Other expenses	0	2	0	0	0	0	0	0	0	0	0	0
Operating income	−134	−384	−261	−107	−120	−79	11	88	163	185	250	325
	363	33	18	1	22	−6	10	12	−16	−36	9	−13
Interest income	27	16	16	13	11	8	13	3	3	58	28	28
Interest expense	0	0	0	0	0	0	7	0	0	0	33	40
Other non-operating income	0	−33	−18	−1	−22	6	−17	−12	16	−28	−42	−27
Income before tax	229	−351	−243	−106	−98	−85	21	100	147	149	259	312
Income tax expense	14	17	8	14	23	67	20	5	22	83	32	75
Net income from continuing operations	215	−368	−251	−120	−121	−152	1	94	125	67	227	237
Net income	215	−368	−251	−120	−121	−152	1	94	125	67	227	237
EPS, basic	$2.08	−$25.48	−$2.47	−$1.15	−$1.16	−$1.43	$0.01	$0.87	$14.69	$7.67	$26.65	$27.04
EPS, diluted	$1.95	−$25.48	−$2.47	−$1.15	−$1.16	−$1.43	$0.01	$0.84	$13.52	$6.76	$25.35	$26.65
Weighted average shares, basic	105	104	104	105	105	106	107	109	110	109	111	112
Weighted average shares, diluted	107	104	104	105	105	106	111	113	115	113	116	116
EBITDA	−112	−327	−218	−82	−27	−35	61	135	184	249	333	393
Depreciation & amortization	22	24	25	24	71	50	33	36	37	36	41	41
EBIT	−134	−351	−243	−106	−98	−85	28	100	147	213	292	352